UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Alzheimer's research & therapy, 2017-12, Vol.9 (1), p.95-95, Article 95

2017

Volltextzugriff (PDF)

Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

The American journal of psychiatry, 2005-03, Vol.162 (3), p.441-449

2005

Volltextzugriff (PDF)

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Alzheimer's research & therapy, 2018-09, Vol.10 (1), p.99-99, Article 99

2018

Volltextzugriff (PDF)

Lifespan persistence of ADHD: the life transition model and its application

The journal of clinical psychiatry, 2012-02, Vol.73 (2), p.192-201

2012

Volltextzugriff (PDF)

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

The international journal of neuropsychopharmacology, 2005-09, Vol.8 (3), p.427-438

2005

Volltextzugriff (PDF)

Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study

The journal of clinical psychiatry, 2013-07, Vol.74 (7), p.694-702

2013

Volltextzugriff (PDF)

Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

Neuropsychopharmacology (New York, N.Y.), 2013-10, Vol.38 (11), p.2140-2149

2013

Volltextzugriff (PDF)

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy

The journal of clinical psychiatry, 1997-04, Vol.58 (4), p.137-145

1997

Volltextzugriff (PDF)

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

Schizophrenia research, 2005-09, Vol.77 (2), p.215-227

2005

Volltextzugriff (PDF)

IDENTIFICATION OF PREDICTORS OF DISEASE PROGRESSION IN AN AMYLOID-BETA 42 (Aβ42)-POSITIVE, PRODROMAL ALZHEIMER’S DISEASE COHORT: ANALYSIS OF THE SCARLET ROAD STUDY

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P829-P829

2016

Volltextzugriff (PDF)

Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation

Neuropsychopharmacology (New York, N.Y.), 2006-11, Vol.31 (11), p.2505-2513

2006

Volltextzugriff (PDF)

FREE AND CUED SELECTIVE REMINDING TEST AS AN INCLUSION CRITERION FOR EARLY ALZHEIMER'S DISEASE CLINICAL TRIAL POPULATIONS

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P343-P344

2016

Volltextzugriff (PDF)

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P198-P198

2016

Volltextzugriff (PDF)

ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

Journal of attention disorders, 2017-01, Vol.21 (1), p.52-61

2017

Volltextzugriff (PDF)

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder

The journal of clinical psychiatry, 2006-08, Vol.67 (8), p.1194-1203

2006

Volltextzugriff (PDF)

Remission in schizophrenia: Applying recent consensus criteria to refine the concept

Schizophrenia research, 2007-11, Vol.96 (1), p.223-231

2007

Volltextzugriff (PDF)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

Annals of general psychiatry, 2007-01, Vol.6 (1), p.3-3, Article 3

2007

Volltextzugriff (PDF)

THE PREDICTIVE UTILITY OF COGNITIVE MEASURES AT SCREENING FOR DETERMINATION OF CSF ABETA (1-42) STATUS IN SUBJECTS WITH PRODROMAL ALZHEIMER'S DISEASE: DATA FROM THE SCARLET ROAD TRIAL

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P821-P822

2016

Volltextzugriff (PDF)

Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

International clinical psychopharmacology, 2006-07, Vol.21 (4), p.233-240

2006

Volltextzugriff (PDF)

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

European psychiatry, 2004-06, Vol.19 (4), p.219-225

2004

Volltextzugriff (PDF)

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

Schizophrenia research, 2005-09, Vol.77 (2), p.119-128

2005

Volltextzugriff (PDF)

Managing ADHD across the Lifespan in the Primary Care Setting

Postgraduate medicine, 2011-09, Vol.123 (5), p.14-26

2011

Volltextzugriff (PDF)

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

International clinical psychopharmacology, 2004-07, Vol.19 (4), p.229-232

2004

Volltextzugriff (PDF)

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

Schizophrenia research, 2005-09, Vol.77 (2), p.129-139

2005

Volltextzugriff (PDF)

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

Schizophrenia research, 2005, Vol.72 (2), p.249-258

2005

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(183)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(131)
Humans
(125)
Female
(97)
Biological And Medical Sciences
(69)
Middle Aged
(69)
Medical Sciences
(66)
Male
(63)
Psychiatry
(56)
Aged
(55)
Adult
(50)
Double-Blind Method
(29)
Treatment Outcome
(29)
Psychology. Psychoanalysis. Psychiatry
(26)
Pharmacology. Drug Treatments
(25)
General & Internal Medicine
(23)
Medicine, General & Internal
(23)
Pharmacology & Pharmacy
(21)
Risk Factors
(21)
Neuropharmacology
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Lifespan persistence of ADHD: the life transition model and its application

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study

Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

IDENTIFICATION OF PREDICTORS OF DISEASE PROGRESSION IN AN AMYLOID-BETA 42 (Aβ42)-POSITIVE, PRODROMAL ALZHEIMER’S DISEASE COHORT: ANALYSIS OF THE SCARLET ROAD STUDY

Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation

FREE AND CUED SELECTIVE REMINDING TEST AS AN INCLUSION CRITERION FOR EARLY ALZHEIMER'S DISEASE CLINICAL TRIAL POPULATIONS

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder

Remission in schizophrenia: Applying recent consensus criteria to refine the concept

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

THE PREDICTIVE UTILITY OF COGNITIVE MEASURES AT SCREENING FOR DETERMINATION OF CSF ABETA (1-42) STATUS IN SUBJECTS WITH PRODROMAL ALZHEIMER'S DISEASE: DATA FROM THE SCARLET ROAD TRIAL

Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

Managing ADHD across the Lifespan in the Primary Care Setting

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

Suchergebnisse filtern